Compare PFAI & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PFAI | CVM |
|---|---|---|
| Founded | 2015 | 1983 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 32.4M |
| IPO Year | N/A | 1996 |
| Metric | PFAI | CVM |
|---|---|---|
| Price | $2.62 | $3.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.4K | ★ 35.8K |
| Earning Date | 05-02-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $1.30 | $0.18 |
| 52 Week High | $4.93 | $13.48 |
| Indicator | PFAI | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 60.53 | 30.83 |
| Support Level | $2.22 | $2.02 |
| Resistance Level | $2.80 | $6.75 |
| Average True Range (ATR) | 0.12 | 0.30 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 82.26 | 3.49 |
Pinnacle Food Group Ltd is a provider of smart farming solutions focused on vertical and hydroponic farming. The company focuses on promoting sustainable food security by developing and building customized smart farming systems for customers based on the systematic integration of technology, hardware, and software, coupled with a full range of integrated supply and technical services. It sells hydroponic growing systems and technical support services to individual households and community groups, and is developing a hydroponic growing system for urban farms. Geographically, the company generates the majority revenue from Canada, followed by New Zealand.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.